Inhibition of staphylothrombin by dabigatran reduces Staphylococcus aureus virulence
Thomas Vanassche, Peter Verhamme(KU Leuven), Alice G. Cheng(University of Chicago), Olaf Schneewind(University of Chicago), Jan Verhaegen(KU Leuven), Marc Hoylaerts(KU Leuven), Joanne van Ryn(Boehringer Ingelheim (Brazil)), Willy Peetermans(KU Leuven)
Cited by 61
Related Papers
American Society of Hematology 2020 Guidelines for Management of Venous Thromboembolism: Treatment of Deep Vein Thrombosis and Pulmonary Embolism
|Blood Advances|2020|1.4k
Idarucizumab for Dabigatran Reversal — Full Cohort Analysis
|New England Journal of Medicine|2017|1.1k
Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors
|New England Journal of Medicine|2019|945